The Pharma Data

SEPTEMBER 16, 2020

Weak healthcare systems in LMICs also hinder timely diagnosis and treatment. This move follows the recent launch of the new Novartis Code of Ethics, and the announcement of a new 2030 target for full carbon neutrality across the company’s entire supply chain.

Therapies 52

Therapies Regulations Government Disease 52

Vial

FEBRUARY 15, 2024

over the forecast period (2022-2030). Factors such as patient access and safety, infrastructure, site experience in clinical research, trial phase requirements, suitability for treatment, and ethical concerns must be carefully considered during site selection3,4.

Pharma Companies 52

Pharma Companies Clinical Trials Compliance Trials 52

The Pharma Data

MARCH 13, 2021

Donanemab has the potential to become a very important treatment for Alzheimer’s disease. ” Specifically, at 76 weeks compared to baseline, treatment with donanemab slowed decline by 32 percent compared to placebo as measured by the iADRS, which was statistically significant. percent), nausea (10.7 In the donanemab arm, 30.5

Disease 40

Disease Trials Treatment Medical Schools 40

Agency IQ

JUNE 28, 2024

Generally, how have states attempted to regulate PFAS? States are attempting to regulate PFAS in a variety of ways, including via multiple in-state regulatory and legislative avenues. In addition, the law prohibits the sale of carpets or fabric treatments containing PFAS as of January 1, 2023.

Production 40

Production Regulations Compliance Packaging 40

Agency IQ

MAY 10, 2024

In general, the law also pushes out a prohibition on almost all products with intentionally added PFAS from January 2030 to January 2032 , except for some cooling, heating, and refrigerant products which will be allowed until 2040. If passed, the law would go into effect in January 2025.

Packaging 40

Packaging Regulations Production Compliance 40

The Pharma Data

JANUARY 9, 2021

RECONCILIATION OF NON-GAAP MEASURES (unaudited) This press release contains two financial measures (Adjusted Net Income and Adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization)) that are considered “non-GAAP” financial measures under applicable Securities and Exchange Commission rules and regulations.

Government 40

Government Vaccine Production Licensing 40

Agency IQ

MARCH 7, 2024

British regulators tease new device regulations in informative live session This week, the British regulator MHRA offered a new peek into its planned medical device regulations. BY COREY JASEPH, MS, RAC | MAR 5, 2024 11:10 PM CST Quick background on medical device regulation in the U.K. post-market regulation here.]

Regulations 40

Regulations International Production Government 40

Agency IQ

DECEMBER 15, 2023

The 174 regulations the EPA is currently working on The Environmental Protection Agency has unveiled its Fall 2023 Unified Agenda, which provides a look into the agency’s regulatory agenda for the upcoming year. The expected release dates of the agendas rarely line up exactly with the actual dates when the agency releases the regulation.

Regulations 40

Regulations Compliance Production Government 40

Agency IQ

DECEMBER 1, 2023

What we expect the EPA to do in December 2023 In this returning feature, AgencyIQ looks at public data to determine what the Environmental Protection Agency is planning to do in the month ahead, including deadlines, meetings, events, planned regulations, comment periods, and more.

Regulations 40

Regulations Production Compliance Science 40

Agency IQ

JUNE 16, 2023

Highlights of the EPA’s Unified Agenda for Spring 2023 The Office of Management and Budget has released the Unified Agenda for Spring 2023, which outlines the regulations that agencies expect to release in 2023 and 2024. This information would be used in considering the regulation of asbestos.

Regulations 40

Regulations Compliance Production Science 40

The Pharma Data

DECEMBER 18, 2020

billion: Norway has signed a new commitment of NOK 1 billion to the International Finance Facility for Immunisation (IFFIm), to be paid from 2021 to 2030. It provides normative guidance on vaccine policy, regulation, safety, R&D, allocation, and country readiness and delivery. million in direct funding and $6.25

Vaccine 52

Vaccine Government International Virus 52